Improved Biomarkers and Clinical Outcome Measures Program

DEADLINE

InReview

The Michael J. Fox Foundation (MJFF) seeks to support research that will develop biomarker tools and clinical outcome measures to assist in diagnosis and therapeutic development and ultimately inform clinical trial design, execution and interpretation of results. Part of our Edmond J. Safra Core Programs for PD Research, the Improved Biomarker and Clinical Outcome Measure program funds research to develop or optimize imaging, clinical, non-invasive or biochemical biomarkers.

Funding will be directed to projects that will improve the precision of measuring Parkinson's disease in humans. This could include enriching subject populations in clinical trials, developing markers of target engagement, or discovery or validation of objective outcomes that track disease progression. Full details are available in the RFA and application template below.

We will begin accepting applications for our next funding cycle on March 11, 2019.

Proposals may aim to achieve the following:

Imaging Studies

Develop novel imaging ligands for disease-modifying or symptomatic targets of interest that would assist in dose selection and efficacy studies

Validate an imaging end-point that identifies a specific stage of the disease or enables quantitative assessment of pathology/pathophysiology or disease progression